Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Grows By 128.9%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 35,432 shares, an increase of 128.9% from the December 15th total of 15,480 shares. Based on an average daily volume of 25,466 shares, the short-interest ratio is presently 1.4 days. Approximately 2.8% of the company’s shares are sold short. Approximately 2.8% of the company’s shares are sold short. Based on an average daily volume of 25,466 shares, the short-interest ratio is presently 1.4 days.

Sonoma Pharmaceuticals Price Performance

SNOA traded up $0.03 during trading on Friday, reaching $3.30. The company had a trading volume of 5,734 shares, compared to its average volume of 16,446. The business’s fifty day moving average price is $3.51 and its 200 day moving average price is $3.78. Sonoma Pharmaceuticals has a 12 month low of $1.75 and a 12 month high of $6.92. The company has a market cap of $5.61 million, a P/E ratio of -1.51 and a beta of 1.61.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.18. Sonoma Pharmaceuticals had a negative return on equity of 45.46% and a negative net margin of 20.57%. As a group, sell-side analysts predict that Sonoma Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 1.95% of the company’s stock.

Analysts Set New Price Targets

SNOA has been the subject of several analyst reports. Wall Street Zen upgraded Sonoma Pharmaceuticals to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.